# Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer

Source: https://onco.cc/trials/nct05725200/  
OnCo record `nct05725200` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Patient-derived organoids in Colorectal cancer, run by Oslo University Hospital, now recruiting.

## Summary

Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer is a phase 2 interventional study registered as NCT05725200 by Oslo University Hospital, with 40 participants planned, started 2022-09-27 and due to reach its primary completion in 2038-12-31. Interventions recorded: Alectinib, Cetuximab, Crizotinib, Dasatinib, Everolimus, Encorafenib, Gemcitabine, Idelalisib, Larotrectinib, Methotrexate, Palbociclib, Panobinostat, Pembrolizumab, Petrozumab, Trastuzumab, Talazoparib, Venetoclax. Conditions recorded: Metastatic Colorectal Cancer.

Linked to the technology Patient-derived organoids because the registry's title names it ("patient derived organoids") and Colorectal cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05725200
- Phase: 2
- Setting: Study to Investigate Outcome of Individualized Treatment Based on Pharmacogenomic Profiling & Ex Vivo Drug Sensitivity Testing of Patient-derived Organoids in Patients With Metastatic Colorectal Cancer
- Sponsor: Oslo University Hospital
- Enrolled: 40

## Sources

- ClinicalTrials.gov NCT05725200: https://clinicaltrials.gov/study/NCT05725200

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- technologies: [Patient-derived organoids](https://onco.cc/technologies/organoids/)
- drugs: [Alectinib](https://onco.cc/drugs/alectinib/), [Cetuximab](https://onco.cc/drugs/cetuximab/), [Crizotinib](https://onco.cc/drugs/crizotinib/), [Dasatinib](https://onco.cc/drugs/dasatinib/), [Encorafenib](https://onco.cc/drugs/encorafenib/), [Everolimus](https://onco.cc/drugs/everolimus/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Idelalisib](https://onco.cc/drugs/idelalisib/), [Larotrectinib](https://onco.cc/drugs/larotrectinib/), [Methotrexate](https://onco.cc/drugs/methotrexate/), [Palbociclib](https://onco.cc/drugs/palbociclib/), [Panobinostat](https://onco.cc/drugs/panobinostat/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [Talazoparib](https://onco.cc/drugs/talazoparib/), [Trastuzumab](https://onco.cc/drugs/trastuzumab/), [Venetoclax](https://onco.cc/drugs/venetoclax/)

---
JSON: https://onco.cc/api/v1/entities/nct05725200.json